Gilead Sciences Q3FY26 Results: Earnings release set for October 29, 2026

0 min read | Published on 16 Oct 2026, 04:16 AM |Updated on 16 Oct 2026, 04:16 AM

Reviewed by

Shriram SScanX News Team

Add as a preferred
source on Google

Key Highlights

Gilead Sciences to release Q3 2026 financial results on October 29, 2026
Management webcast scheduled for 4:30 pm Eastern Time on the same day
Live webcast available via the Investors section of the company website
Recording archived for one year post-event

*this image is generated using AI for illustrative purposes only.

Gilead Sciences announced that its third quarter 2026 financial results and guidance will be released on Thursday, October 29, 2026, after the market closes.

The biopharmaceutical company stated that management will host a webcast to discuss the quarterly financial results and provide a business update. The session is scheduled for 4:30 pm Eastern Time on the same day as the earnings release.

Webcast availability

A live webcast of the event will be accessible in the Investors section of the company's official website. The recording will remain archived for one year following the broadcast date.

Company profile

Gilead Sciences is a biopharmaceutical company focused on advancing innovative medicines to prevent and treat life-threatening diseases. Its therapeutic areas include HIV, viral hepatitis, COVID-19, and cancer. The company operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

How might Gilead's Q3 2026 HIV and oncology pipeline updates influence its long-term revenue diversification strategy?

What impact could anticipated changes in global healthcare reimbursement policies have on Gilead's international market growth?

How will Gilead's capital allocation plans, such as dividends or share buybacks, be adjusted following the upcoming earnings release?

View Company Insights

View All News

Gilead Sciences delivers 16.24% annualized return over five years

1 min read | Published on 21 Sept 2026, 09:08 PM |Updated on 21 Sept 2026, 09:08 PM

Reviewed by

Ritika DScanX News Team

Add as a preferred
source on Google

Key Highlights

Gilead Sciences posted a 16.24% average annual return over five years
The stock outperformed the broader market by 4.6% annually
A $1,000 investment from five years ago is now worth $2,107.34
Current market capitalization stands at $185.37 billion

*this image is generated using AI for illustrative purposes only.

Gilead Sciences (NASDAQ: GILD) has generated an average annual return of 16.24% over the past five years. This performance outpaced the broader market by 4.6% on an annualized basis.

The biopharmaceutical company currently holds a market capitalization of $185.37 billion. The stock price stood at $149.50 at the time of writing.

Investment Performance

An investor who purchased $1,000 of GILD stock five years ago would hold assets worth $2,107.34 today. This calculation reflects the total return including price appreciation and any reinvested dividends over the period.

Metric	Value
Annualized Return	16.24%
Market Outperformance	4.6%
Current Market Cap	$185.37 billion
Current Share Price	$149.50

What the Numbers Show

The data illustrates the compounding effect of consistent outperformance. While the absolute gain of $1,107.34 on a $1,000 investment appears modest in isolation, it represents a doubling of capital value in real terms relative to the initial outlay when adjusted for the specific price points disclosed. The 4.6% annualized excess return over the market benchmark underscores the stock's ability to generate alpha during this five-year window.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

Can Gilead Sciences sustain its 16.24% annualized return as its blockbuster HIV and hepatitis drugs face increasing generic competition?

How will the company's pipeline of novel therapies in oncology and immunology impact its future revenue growth trajectory?

Is the current $185 billion market capitalization fully valued given the potential risks associated with patent cliffs in its core portfolio?

View Company Insights

View All News